PF-06650833 is an inhibitor ofInterleukin-1 receptor associated kinase 4 (IRAK4), and used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Zimlovisertib (PF-06650833) is a potent, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), showing IC50 values of 0.2 nM in cell assays and 2.4 nM in peripheral blood mononuclear cell (PBMC) assays. It is primarily aimed at treating conditions such as rheumatoid arthritis, lupus, and lymphomas[1].[2]. |
Animal study | Oral administration of Zimlovisertib (0.3-30 mg/kg) to male Sprague-Dawley rats significantly suppressed LPS-induced TNF-α production in a dose-dependent manner. Plasma concentrations of Zimlovisertib were measured at 2.1 nM, 7.7 nM, 19 nM, and 150 nM free, respectively, 2.5 hours post-administration at the aforementioned dosages. The fraction of Zimlovisertib unbound in rat plasma was determined to be 0.3[1]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.77mL 0.55mL 0.28mL |
13.84mL 2.77mL 1.38mL |
27.67mL 5.53mL 2.77mL |
CAS号 | 1817626-54-2 |
分子式 | C18H20FN3O4 |
分子量 | 361.37 |
SMILES Code | O=C(C1=CC2=C(C(OC[C@H]([C@H](CC)[C@@H]3F)NC3=O)=NC=C2)C=C1OC)N |
MDL No. | MFCD30343869 |
别名 | PF-06650833 |
运输 | 蓝冰 |
InChI Key | JKDGKIBAOAFRPJ-ZBINZKHDSA-N |
Pubchem ID | 118414016 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, 2-8°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|